These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32066715)

  • 81. The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: data from multicenter, prospective, longitudinal clinic practice.
    Li Z; Zhang Y; Wang Z; Chen J; Fan J; Guan Y; Zhang C; Yuan C; Hong W; Wang Y; Wu Z; Huang J; Hu Y; Cao L; Yi Z; Cui D; Yu S; Fang Y
    J Psychiatr Res; 2013 Jan; 47(1):8-14. PubMed ID: 23137999
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Courses of treatment and risk factors for treatment-resistant depression in Finnish primary and special healthcare: A nationwide cohort study.
    Lähteenvuo M; Taipale H; Tanskanen A; Rannanpää S; Tiihonen J
    J Affect Disord; 2022 Jul; 308():236-242. PubMed ID: 35398108
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US.
    Shah D; Allen L; Zheng W; Madhavan SS; Wei W; LeMasters TJ; Sambamoorthi U
    Pharmacoeconomics; 2021 Jun; 39(6):639-651. PubMed ID: 33904144
    [TBL] [Abstract][Full Text] [Related]  

  • 84. One-year incidence rate of Treatment Resistant Depression (TRD) and treatment characteristics in China.
    Wang H; Wu T; Dong S; Guan M; Liu A; Jiang K; Chi R; Qiu H; Dong W; Si T
    J Affect Disord; 2022 May; 305():77-84. PubMed ID: 35240201
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach.
    McIntyre RS; Filteau MJ; Martin L; Patry S; Carvalho A; Cha DS; Barakat M; Miguelez M
    J Affect Disord; 2014 Mar; 156():1-7. PubMed ID: 24314926
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome.
    Kiraly DD; Horn SR; Van Dam NT; Costi S; Schwartz J; Kim-Schulze S; Patel M; Hodes GE; Russo SJ; Merad M; Iosifescu DV; Charney DS; Murrough JW
    Transl Psychiatry; 2017 Mar; 7(3):e1065. PubMed ID: 28323284
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The burden of treatment-resistant depression: A systematic review of the economic and quality of life literature.
    Johnston KM; Powell LC; Anderson IM; Szabo S; Cline S
    J Affect Disord; 2019 Jan; 242():195-210. PubMed ID: 30195173
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Understanding the Relationship Between Depression Symptom Severity and Health Care Costs for Patients With Treatment-Resistant Depression.
    Lynch FL; Dickerson JF; O'Keeffe-Rosetti M; Chow W; Pesa J
    J Clin Psychiatry; 2022 Feb; 83(2):. PubMed ID: 35120286
    [No Abstract]   [Full Text] [Related]  

  • 89. Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database.
    Amos TB; Tandon N; Lefebvre P; Pilon D; Kamstra RL; Pivneva I; Greenberg PE
    J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29474009
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
    McIntyre RS; Lipsitz O; Lui LMW; Rodrigues NB; Lee Y; Ho RC; Subramaniapillai M; Gill H; Cha DS; Lin K; Teopiz KM; Nasri F; Mansur RB; Kratiuk K; Rosenblat JD
    J Affect Disord; 2021 Sep; 292():714-719. PubMed ID: 34161889
    [TBL] [Abstract][Full Text] [Related]  

  • 92. What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram.
    Souery D; Calati R; Papageorgiou K; Juven-Wetzler A; Gailledreau J; Modavi D; Sentissi O; Pitchot W; Papadimitriou GN; Dikeos D; Montgomery S; Kasper S; Zohar J; Serretti A; Mendlewicz J
    World J Biol Psychiatry; 2015 Oct; 16(7):472-82. PubMed ID: 25535987
    [TBL] [Abstract][Full Text] [Related]  

  • 93. How well do clinical and demographic characteristics predict Patient Health Questionnaire-9 scores among patients with treatment-resistant major depressive disorder in a real-world setting?
    Voelker J; Joshi K; Daly E; Papademetriou E; Rotter D; Sheehan JJ; Kuvadia H; Liu X; Dasgupta A; Potluri R
    Brain Behav; 2021 Feb; 11(2):e02000. PubMed ID: 33403828
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Copper and anti-anhedonic effect of ketamine in treatment-resistant depression.
    Słupski J; Cubała WJ; Górska N; Słupska A; Gałuszko-Węgielnik M
    Med Hypotheses; 2020 Nov; 144():110268. PubMed ID: 33254572
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics.
    de Sousa RT; Zanetti MV; Brunoni AR; Machado-Vieira R
    Curr Neuropharmacol; 2015; 13(5):616-35. PubMed ID: 26467411
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study.
    Kautzky A; Dold M; Bartova L; Spies M; Kranz GS; Souery D; Montgomery S; Mendlewicz J; Zohar J; Fabbri C; Serretti A; Lanzenberger R; Dikeos D; Rujescu D; Kasper S
    Acta Psychiatr Scand; 2019 Jan; 139(1):78-88. PubMed ID: 30291625
    [TBL] [Abstract][Full Text] [Related]  

  • 97. The Dutch Measure for quantification of Treatment Resistance in Depression (DM-TRD): an extension of the Maudsley Staging Method.
    Peeters FP; Ruhe HG; Wichers M; Abidi L; Kaub K; van der Lande HJ; Spijker J; Huibers MJ; Schene AH
    J Affect Disord; 2016 Nov; 205():365-371. PubMed ID: 27568174
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Elevated tumor necrosis factor-alpha receptor subtype 1 and the association with abnormal brain function in treatment-resistant depression.
    Huang MH; Chen MH; Tu PC; Bai YM; Su TP; Yang BH; Liu RS; Li CT
    J Affect Disord; 2018 Aug; 235():250-256. PubMed ID: 29660639
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Genetics of antidepressant response and treatment-resistant depression.
    Chung AN; Chen TT; Lin YF
    Prog Brain Res; 2023; 278():25-60. PubMed ID: 37414493
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials.
    Sforzini L; Worrell C; Kose M; Anderson IM; Aouizerate B; Arolt V; Bauer M; Baune BT; Blier P; Cleare AJ; Cowen PJ; Dinan TG; Fagiolini A; Ferrier IN; Hegerl U; Krystal AD; Leboyer M; McAllister-Williams RH; McIntyre RS; Meyer-Lindenberg A; Miller AH; Nemeroff CB; Normann C; Nutt D; Pallanti S; Pani L; Penninx BWJH; Schatzberg AF; Shelton RC; Yatham LN; Young AH; Zahn R; Aislaitner G; Butlen-Ducuing F; Fletcher C; Haberkamp M; Laughren T; Mäntylä FL; Schruers K; Thomson A; Arteaga-Henríquez G; Benedetti F; Cash-Gibson L; Chae WR; De Smedt H; Gold SM; Hoogendijk WJG; Mondragón VJ; Maron E; Martynowicz J; Melloni E; Otte C; Perez-Fuentes G; Poletti S; Schmidt ME; van de Ketterij E; Woo K; Flossbach Y; Ramos-Quiroga JA; Savitz AJ; Pariante CM
    Mol Psychiatry; 2022 Mar; 27(3):1286-1299. PubMed ID: 34907394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.